Category: PRESS RELEASES

17
April 2024
Enterome Announces Successful Completion of Phase 2 ROSALIE Study of EO2401 in Recurrent Glioblastoma
Read more
06
March 2024
Enterome Announces Upcoming Presentation on OncoMimics™ Approach to Cancer Immunotherapy at the AACR Annual Meeting 2024
Read more
18
December 2023
Enterome Appoints Industry Veteran Dr. Peter Hirth to its Board of Directors
Read more
20
November 2023
Enterome’s OncoMimics™ Immunotherapy EO2401 Significantly Improves Survival Rate in Recurrent Glioblastoma
Read more
13
November 2023
Enterome to Present Updated Data From Phase 1/2 ROSALIE Trial of its Peptide-Based Immunotherapy EO2401 in Recurrent Glioblastoma at SNO 2023
Read more
01
November 2023
Enterome Presents Immune-Monitoring Data on EO2401 at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Read more
30
October 2023
Enterome Selected to The Leukemia & Lymphoma Society’s Therapy Acceleration Program
Read more
25
October 2023
Enterome to Present Clinical Progress on its OncoMimics™ Pipeline at Upcoming Investor Meetings
Read more
23
October 2023
Enterome Presents Positive Data from Phase 1/2 SPENCER Trial of EO2401 in Adrenal Tumors at ESMO 2023 Congress
Read more

Enterome

Headquarters
94/96 avenue Ledru-Rollin 75011 Paris – France
Tel: +33 (0)1 75 77 27 85
Email: info@enterome.com
Metro Station: Ledru-Rollin (Line 8)